R&D channel feed

NGM tabled its NASH pro­gram in 2021 af­ter a key tri­al fail­ure. Now it’s re­port­ing suc­cess in a sec­ond study

3 years ago

Fi­bro­Gen’s rox­adu­s­tat fails a PhI­II clin­i­cal tri­al

3 years ago

Bay­er opens cell, gene ther­a­py in­cu­ba­tor in Cam­bridge

3 years ago

With Eylea in de­cline, Re­gen­eron awaits FDA ap­proval for high­er dose of block­buster

3 years ago
Pharma

NIH con­tributes bil­lions to new drug de­vel­op­ment. GAO says patents don't tell the full sto­ry

3 years ago

Io­n­is chops two PhII pro­grams in acromegaly and be­ta tha­lassemia

3 years ago

Roche dou­bles down on organoids, hu­man mod­el sys­tems with new re­search in­sti­tute

3 years ago
Discovery
Pharma

Val­ne­va, Pfiz­er de­lay their Ly­me dis­ease vac­cine sub­mis­sion to 2026

3 years ago
Pharma

Bellde­grun-backed biotech re­al es­tate group nabs $130M to con­struct eight-sto­ry hub in Philly

3 years ago

“The grim veil has been lift­ed.” Ex­cite­ment, and ques­tions, mount over Lil­ly’s pos­i­tive Alzheimer’s drug da­ta

3 years ago

Im­muno­Gen’s ovar­i­an can­cer treat­ment helps pa­tients live longer than chemo in con­fir­ma­to­ry tri­al

3 years ago

Lil­ly’s Alzheimer’s drug do­nanemab slows cog­ni­tive de­cline by 35% in PhI­II, set­ting up show­down with Ei­sai’s Leqem­bi

3 years ago

De­cen­tral­ized tri­als: FDA lays out its think­ing in new draft guid­ance

3 years ago
FDA+

Boehringer In­gel­heim to con­struct a $300M+ fa­cil­i­ty at its HQ

3 years ago
Manufacturing

In­cyte cuts fi­nal tri­al for PI3K drug more than a year af­ter yank­ing ac­cel­er­at­ed ap­proval fil­ing

3 years ago

Pfiz­er culls some Are­na-ac­quired pro­grams as it looks to­ward new launch­es

3 years ago
Pharma

Im­mat­ics spikes on a round of promis­ing — but still ear­ly — au­tol­o­gous cell ther­a­py da­ta for sol­id tu­mors

3 years ago
Cell/Gene Tx

IMV finds 'breath­ing room' to look for deals or in­vest­ments, will not en­roll new pa­tients in PhI­Ib can­cer vac­cine tri­als

3 years ago

Tra­vere miss­es pri­ma­ry end­point in PhI­II for rare kid­ney dis­ease but the com­pa­ny is still con­sid­er­ing a 'path for­ward'

3 years ago

Bris­tol My­er­s' CAR-T Breyanzi hits end­points in two lym­phoma stud­ies

3 years ago
Pharma
Cell/Gene Tx

Bi­par­ti­san bill seeks to curb drug short­ages with more in­fo to FDA on spikes in de­mand

3 years ago
Manufacturing

Cor­rect­ed: 'A piece of plas­tic with a 40-year-old drug in it': J&J touts promis­ing ear­ly da­ta for blad­der can­cer treat­ment

3 years ago

Pli­ant Ther­a­peu­tics re­leas­es longer-term safe­ty, pre­lim­i­nary ef­fi­ca­cy da­ta from PhI­Ia study

3 years ago

Pfiz­er, Astel­las say Xtan­di drug com­bo re­duces risk of metas­ta­sis, death in prostate can­cer by 58%

3 years ago
First page Previous page 88899091929394 Next page Last page
A service from the Financial Times